Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 56.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,890 shares of the company’s stock after selling 11,477 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Kiniksa Pharmaceuticals were worth $176,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter worth approximately $158,000. Teacher Retirement System of Texas grew its stake in Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after buying an additional 719 shares during the last quarter. Globeflex Capital L P increased its position in Kiniksa Pharmaceuticals by 217.1% in the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock worth $1,752,000 after buying an additional 60,656 shares during the period. Raymond James Financial Inc. bought a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at $3,955,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Kiniksa Pharmaceuticals by 36.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock valued at $2,414,000 after acquiring an additional 32,393 shares during the period. Institutional investors own 53.95% of the company’s stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the sale, the chief operating officer now directly owns 88,975 shares of the company’s stock, valued at $1,622,904. The trade was a 13.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total value of $809,277.00. Following the transaction, the chief financial officer now owns 22,958 shares in the company, valued at $510,815.50. This represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,766 shares of company stock worth $2,011,735. Company insiders own 54.57% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on KNSA. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock opened at $23.41 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $16.56 and a 1 year high of $28.15. The business’s fifty day moving average is $20.40 and its 200-day moving average is $22.00. The stock has a market cap of $1.70 billion, a PE ratio of -167.20 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same quarter in the previous year, the firm earned $0.35 earnings per share. The business’s revenue was up 46.9% compared to the same quarter last year. Equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.